Technology
Health
Biotechnology

ChemoCentryx

$10.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.41 (3.90%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ChemoCentryx and other stocks, options, ETFs, and crypto commission-free!

About

ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. Read More It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Employees
76
Headquarters
Mountain View, California
Founded
1996
Market Cap
552.62M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
271.63K
High Today
$11.04
Low Today
$10.45
Open Price
$10.52
Volume
319.72K
52 Week High
$14.51
52 Week Low
$9.07

Collections

Technology
Health
Biotechnology
Top Movers
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US

News

Seeking AlphaMar 12

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2018 Results - Earnings Call Transcript

ChemoCentryx, Inc. (NASDAQ:CCXI) Q4 2018 Earnings Conference Call March 11, 2019 5:00 PM ET Company Participants William Slattery - Investor Relations, Burns McClellan Inc. Thomas Schall - Chairman, President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Financial and Administrative Officer and Secretary Conference Call Participants Lina Kaminski - Canaccord Genuity LLC Steven Seedhouse - Raymond James & Associates, Inc. Dae Gon Ha - SVB Leerink LLC Edward Tenthoff - Pi...

26
The Motley FoolMar 12

ChemoCentryx (CCXI) Q4 2018 Earnings Conference Call Transcript

CHEMOCENTRYX INC (NASDAQ:CCXI) Q4 2018 Earnings Conference Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the ChemoCentryx Fourth Quarter and Full Year 2018 Financial Results Conference Call. At this time, all participants on a listen-only mode. Later, we'll conduct a question-and-answer session. As a reminder, this conference will be recorded. I would now like turn the call over to your host, Bill Sl...

12
Seeking AlphaMar 11

ChemoCentryx, Inc. beats by $0.06, misses on revenue

ChemoCentryx, Inc. (NASDAQ:CCXI): Q4 GAAP EPS of -$0.21 beats by $0.06. Revenue of $9.33M (-83.4% Y/Y) misses by $0.12M . Press Release...

35

Earnings

-$0.27
$0.09
$0.44
$0.80
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.27 per share
Actual
-$0.21 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.